Anatomical Therapeutic Chemical • S01LA04 • ranibizumab

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

L Antineoplastic and immunomodulating agents

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

S01 Ophthalmologicals

S01A Antiinfectives

S01B Antiinflammatory agents

S01C Antiinflammatory agents and antiinfectives in combination

S01E Antiglaucoma preparations and miotics

S01F Mydriatics and cycloplegics

S01G Decongestants and antiallergics

S01H Local anesthetics

S01J Diagnostic agents

S01K Surgical aids

S01L Ocular vascular disorder agents

S01LA Antineovascularisation agents

S01LA01 verteporfin Indicated for: macular degeneration; diabetic macular edema

S01LA03 pegaptanib sodium Indicated for: macular degeneration; diabetic macular edema

S01LA04 ranibizumab Indicated for: macular degeneration; diabetic macular edema

S01LA05 aflibercept Indicated for: macular degeneration; diabetic macular edema

S01LA06 brolucizumab Indicated for: macular degeneration; diabetic macular edema

S01LA09 faricimab Indicated for: macular degeneration; diabetic macular edema

S01X Other ophthalmologicals

S02 Otologicals

S03 Ophthalmological and otological preparations

V Various